These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33954116)

  • 1. Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer.
    Henkenberens C; Derlin T; Bengel F; Ross TL; Kuczyk MA; Giordano FA; Sarria GR; Schmeel LC; Christiansen H; von Klot CAJ
    Front Oncol; 2021; 11():664225. PubMed ID: 33954116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
    Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
    Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Progression After
    Soldatov A; von Klot CAJ; Walacides D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; Christiansen H; Henkenberens C
    Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):95-104. PubMed ID: 30201438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Artigas C; Flamen P; Charlier F; Levillain H; Wimana Z; Diamand R; Albisinni S; Gil T; Velthoven RV; Peltier A; Gestel DV; Roumeguere T; Otte FX
    World J Urol; 2019 Aug; 37(8):1535-1542. PubMed ID: 30824985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer.
    Nikitas J; Castellanos Rieger A; Farolfi A; Seyedroudbari A; Kishan AU; Nickols NG; Steinberg ML; Valle LF; Rettig M; Czernin J; Calais J
    J Nucl Med; 2024 Sep; 65(9):1387-1394. PubMed ID: 39089811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.
    Henkenberens C; von Klot CA; Ross TL; Bengel FM; Wester HJ; Merseburger AS; Vogel-Claussen J; Christiansen H; Derlin T
    Strahlenther Onkol; 2016 Jul; 192(7):431-9. PubMed ID: 27272755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer.
    Sheikh GT; Trapp C; Schmidt-Hegemann NS; Buchner A; Stief CG; Unterrainer M; Kunz WG; Cyran CC; Grawe F; Delker A; Zacherl MJ; Holzgreve A; Unterrainer LM; Brendel M; Belka C; Li M; Rogowski P
    EJNMMI Rep; 2024 Aug; 8(1):25. PubMed ID: 39155339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer.
    Deijen CL; Vrijenhoek GL; Schaake EE; Vogel WV; Moonen LMF; Pos FJ; van der Poel HG; Borst GR
    Clin Transl Radiat Oncol; 2021 Sep; 30():1-6. PubMed ID: 34278008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response assessment using
    Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy, prognostic variables and clinical outcome of
    Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
    Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.
    Guler OC; Engels B; Onal C; Everaert H; Van den Begin R; Gevaert T; de Ridder M
    Clin Transl Oncol; 2018 Apr; 20(4):484-490. PubMed ID: 28795303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
    Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response assessment using [
    Grubmüller B; Rasul S; Baltzer P; Fajkovic H; D'Andrea D; Berndl F; Maj-Hes A; Grubmüller KH; Mitterhauser M; Wadsak W; Pfaff S; Shariat SF; Hacker M; Kramer G; Hartenbach M
    Prostate; 2020 Jan; 80(1):74-82. PubMed ID: 31614001
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
    Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
    [No Abstract]   [Full Text] [Related]  

  • 19.
    Caroli P; Colangione SP; De Giorgi U; Ghigi G; Celli M; Scarpi E; Monti M; Di Iorio V; Sarnelli A; Paganelli G; Matteucci F; Romeo A
    Biomedicines; 2020 Nov; 8(12):. PubMed ID: 33255681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients.
    Natarajan A; Agrawal A; Murthy V; Bakshi G; Joshi A; Purandare N; Shah S; Puranik A; Rangarajan V
    World J Nucl Med; 2019; 18(3):244-250. PubMed ID: 31516367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.